Clinical Trial

Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This randomized controlled phase III trial aims to evaluate the use of electroacupuncture in combination with olanzapine-containing standard quadruple antiemetic drugs for the treatment of nausea and vomiting induced by highly emetogenic chemotherapy (HEC) in patients with breast cancer. Furthermore, it will analyze the relationship between single nucleotide polymorphism and electroacupuncture treatment for chemotherapy-induced nausea and vomiting.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-29.
Trial Details
NCT Number NCT06200168
Lead Sponsor Jiuda Zhao
Conditions Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting
Enrollment 370 participants
Start Date 2024-01-16
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-02